Stay updated on Azacitidine + Pembrolizumab in AML Clinical Trial
Sign up to get notified when there's something new on the Azacitidine + Pembrolizumab in AML Clinical Trial page.

Latest updates to the Azacitidine + Pembrolizumab in AML Clinical Trial page
- Check3 days agoChange DetectedThe site footer revision label was updated from v3.8.0 to v3.8.1, with the clinical trial record unchanged.SummaryDifference0.1%

- Check10 days agoChange DetectedThe record now provides details of the completed phase 2 azacitidine–pembrolizumab study, including its cohorts, eligibility criteria, locations, outcomes, and study documents.SummaryDifference59%

- Check17 days agoChange DetectedThe footer's site revision identifier changed from v3.7.2 to v3.8.0, while the page continues to display a 403 error.SummaryDifference0.2%

- Check31 days agoChange DetectedA general NIH notice about using “Super Intelligence” instead of “Artificial Intelligence” appears on the page, and the site revision changes from v3.7.1 to v3.7.2.SummaryDifference1%

- Check45 days agoChange DetectedThe footer revision identifier updates from v3.7.0 to v3.7.1 while the page continues to display a 403 error.SummaryDifference0.2%

- Check59 days agoChange DetectedThe page now displays a 403 Forbidden error with standard site chrome, replacing the usual study record content. This indicates that access to the page is blocked.SummaryDifference20%

Stay in the know with updates to Azacitidine + Pembrolizumab in AML Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Azacitidine + Pembrolizumab in AML Clinical Trial page.